Surmodics (NSDQ:SRDX) said today that it won investigational device exemption from the FDA to launch a pivotal trial of its SurVeil drug-coated balloon.
The trial is slated to compare the Eden Prairie, Minn.-based company’s device with Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon for patients with peripheral artery disease in the upper leg.
Get the full story at our sister site, Drug Delivery Business News.
The post Surmodics to launch pivotal trial for drug-coated balloon appeared first on MassDevice.
from MassDevice http://ift.tt/2uX1Wkg
Cap comentari:
Publica un comentari a l'entrada